GT Biopharma Stock Forecast, Price & News

+0.26 (+2.70 %)
(As of 04/22/2021 12:00 AM ET)
Today's Range
Now: $9.90
50-Day Range
MA: $7.38
52-Week Range
Now: $9.90
Volume386,305 shs
Average Volume467,255 shs
Market Capitalization$66.51 million
P/E RatioN/A
Dividend YieldN/A
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology products based on its proprietary technology platforms. The company develops immuno-oncology product candidates, including GTB-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors, which is in Phase 2 clinical trial; GTB-3550, a single-chain, tri-specific scFv recombinant fusion protein conjugate that is in Phase 1 clinical trial; GTB-C3550, a next-generation follow-on to its lead candidates TriKE, GTB-3550, and GTB-C3550, which contains a modified CD16 moiety; and GTB-1615, a single-chain fusion protein for the treatment of solid tumors. Its central nervous system portfolio consists of GTP-004 for the treatment of myasthenia gravis, PainBrake to treat chronic neuropathic pain, and GTP-011 for the treatment of motion sickness. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a novel 161533 TriKE fusion protein for cancer therapies; and a collaboration agreement with Cytovance Biologics to provide development services for a TriKE therapeutic for the treatment of coronavirus infection. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is headquartered in Westlake Village, California.
GT Biopharma logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolOTCMKTS:GTBP
Previous SymbolOTCMKTS:OXISD
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value($0.29) per share


Net Income$-38,650,000.00


Market Cap$66.51 million
Next Earnings DateN/A
OptionableNot Optionable


GT Biopharma (OTCMKTS:GTBP) Now Covered by B. Riley
April 13, 2021 |  americanbankingnews.com
GT Biopharma Inc
February 24, 2021 |  reuters.com
GT Biopharma Appoints Two New Independent Directors
January 19, 2021 |  finance.yahoo.com
Biotech Shares Pop On New Patent Announcement
December 29, 2020 |  baystreet.ca
See More Headlines


Overall MarketRank

1.18 out of 5 stars

Medical Sector

944th out of 2,024 stocks

Pharmaceutical Preparations Industry

444th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
+0.26 (+2.70 %)
(As of 04/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GTBP News and Ratings via Email

Sign-up to receive the latest news and ratings for GTBP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

GT Biopharma (OTCMKTS:GTBP) Frequently Asked Questions

Is GT Biopharma a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GT Biopharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GT Biopharma stock.
View analyst ratings for GT Biopharma
or view top-rated stocks.

What stocks does MarketBeat like better than GT Biopharma?

Wall Street analysts have given GT Biopharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but GT Biopharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were GT Biopharma's earnings last quarter?

GT Biopharma, Inc. (OTCMKTS:GTBP) announced its quarterly earnings results on Thursday, April, 15th. The company reported ($3.39) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.04) by $3.35.
View GT Biopharma's earnings history

How has GT Biopharma's stock price been impacted by COVID-19 (Coronavirus)?

GT Biopharma's stock was trading at $0.1880 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, GTBP stock has increased by 5,166.0% and is now trading at $9.90.
View which stocks have been most impacted by COVID-19

What price target have analysts set for GTBP?

2 analysts have issued twelve-month price targets for GT Biopharma's stock. Their forecasts range from $21.00 to $25.00. On average, they expect GT Biopharma's stock price to reach $23.00 in the next twelve months. This suggests a possible upside of 132.3% from the stock's current price.
View analysts' price targets for GT Biopharma
or view top-rated stocks among Wall Street analysts.

Who are GT Biopharma's key executives?

GT Biopharma's management team includes the following people:
  • Mr. Anthony J. Cataldo, Chairman, CEO & Pres (Age 69, Pay $362k)
  • Mr. Michael D. Handelman, CFO & Principal Accounting Officer (Age 62, Pay $528.25k)
  • Mr. Martin Schroeder, Chief Technology Officer (Age 68)
  • Dr. Jeffrey S. Miller M.D., Consulting Chief Medical Officer & Scientific Advisor

Who are some of GT Biopharma's key competitors?

What other stocks do shareholders of GT Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GT Biopharma investors own include Cronos Group (CRON), (CGC), Canopy Growth (WEED), Auxly Cannabis Group (CBWTF), KushCo (KSHB), Aurora Cannabis (ACBFF), Alibaba Group (BABA), Cara Therapeutics (CARA), American Cannabis (AMMJ) and GW Pharmaceuticals (GWPH).

What is GT Biopharma's stock symbol?

GT Biopharma trades on the OTCMKTS under the ticker symbol "GTBP."

How do I buy shares of GT Biopharma?

Shares of GTBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GT Biopharma's stock price today?

One share of GTBP stock can currently be purchased for approximately $9.90.

How much money does GT Biopharma make?

GT Biopharma has a market capitalization of $66.51 million.

How many employees does GT Biopharma have?

GT Biopharma employs 2 workers across the globe.

What is GT Biopharma's official website?

The official website for GT Biopharma is www.gtbiopharma.com.

Where are GT Biopharma's headquarters?

GT Biopharma is headquartered at 9350 Wilshire Blvd. Suite 203, Beverly Hills CA, 90212.

How can I contact GT Biopharma?

GT Biopharma's mailing address is 9350 Wilshire Blvd. Suite 203, Beverly Hills CA, 90212. The company can be reached via phone at 800-304-9888 or via email at [email protected]

This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.